Letter to the editor concerning the article: ‘Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)’.

HOME
>
論文・技術情報
>
Letter to the editor concerning the article: ‘Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)’.

アブストラクト
ジャーナル名	British journal of clinical pharmacology
投稿日	2023/4/28
投稿者	Sinvhal, Ranjeeta; Krueger, Whitney S; Kilpatrick, Ryan D; Coppola, Danielle
組織名	AbbVie, Inc., North Chicago, Illinois, USA.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/37114281/

タグ:

お問合わせ

キーワード